{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Peptide Show","title":"Ksenia Petrushkina: Why are teenagers injecting peptides?","html":"","width":"100%","height":180,"duration":1666,"description":"What happens when people start experimenting with peptides before seeing a clinician? \n\nKsenia Petrushkina sees the impact of peptides up close.\nAs Director of Regenerative Medicine at Ideal Medical in Miami, she works with patients using peptides, longevity therapeutics, and regenerative medicine, including people who arrive after already starting protocols they found online.\nBefore clinical medicine, Ksenia worked in cancer research. It taught her a lesson that still shapes how she thinks about peptides today: what looks extraordinary in a laboratory can fall apart completely in the real world.\nNow she sees the problem from the other direction. Patients arrive with gray-market vials, protocols copied from influencers, and stacks containing multiple experimental compounds. Some are teenagers.\nKsenia is not anti-peptide. But she believes enthusiasm is moving faster than the evidence, and that separating promising biology from what is actually proven in humans will determine the future of peptide medicine.\nShe explains:\n\n■ Why teenagers are buying and injecting peptides they find online\n■ Why she has serious reservations about MOTS-c and other heavily promoted compounds\n■ Why promising results in petri dishes and mice can fall apart in humans\n■ Why stacking multiple peptides makes benefits and side effects almost impossible to untangle\n■ Why better safety data and real-world reporting could determine the future of peptide medicine\nChapters\n\n\n\nFurther reading\n\nFDA: July 2026 Pharmacy Compounding Advisory Committee review covering BPC-157, TB-500, MOTS-c, and other peptide-related bulk substances: FDA PCAC July 2026 meeting\n\nFDA: Current concerns around unapproved GLP-1 drugs, including retatrutide: FDA: Concerns with unapproved GLP-1 drugs\n\nPubMed: Review of the safety, evidence, and regulatory status of approved and unapproved peptide therapies: Safety and Efficacy of Approved and Unapproved Peptide Therapies\n\nPubMed: 2025 pilot study of intravenous BPC-157 in two...","thumbnail_url":"https://img.transistorcdn.com/QcXtaDr9qe6jHT4c0BxQri4VufvdedcvMTMLmbuyqSA/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mZTg2/YmYyODMzN2NhMDNh/NzMzZGUxMzJhNDFj/YjVmMS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}